PASG

Passage BIO, Inc. (PASG) - Q1 2025 Filing Summary

Business Context and Reporting Period

This summary covers the Quarterly Report on Form 10-Q for Passage BIO, Inc. for the period ended March 31, 2025. Passage BIO is a clinical-stage genetic medicines company focused on developing one-time therapies for neurodegenerative diseases. Its lead product candidate, PBFT02, targets frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN). The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Note: The company has no commercial revenue. Cash increased due to the maturity of marketable securities and proceeds from asset sales, offset by operating losses.

Material Changes vs. Prior Period

• Restructuring and Workforce Reduction: In January 2025, the company announced a 55% workforce reduction and ceased laboratory operations in Hopewell, New Jersey. This resulted in a one-time $2.6 million impairment charge for long-lived assets (laboratory equipment) and approximately $1.7 million in severance costs included in operating expenses.
• Expense Reduction: Research and Development (R&D) expenses decreased by $3.8 million (33%) to $7.7 million, driven by the termination of discovery research obligations with the University of Pennsylvania, reduced headcount, and ceased lab operations. General and Administrative (G&A) expenses decreased by $0.4 million to $6.1 million.
• Asset Liquidation: The company sold substantially all laboratory equipment for $1.2 million. As of March 31, 2025, $0.6 million of proceeds remained outstanding. All marketable securities matured during the quarter, with proceeds reinvested into cash equivalents.
• Outlicense Transaction: The company received $5.0 million in initial payments and $3.7 million in transition services payments from Gemma Biotherapeutics, Inc. These funds are recorded as liabilities ("non-refundable sublicense and transition services payments received") as revenue recognition criteria have not yet been met.

Guidance, Outlook, and Risks

• Cash Runway: Management expects existing cash and cash equivalents ($63.4 million) to fund operating expenses and capital expenditures into the first quarter of 2027.
• Clinical Progress:
  • FTD-GRN: Dose 1 of PBFT02 showed robust increases in CSF progranulin levels. Dose 2 (50% lower than Dose 1) has begun dosing. The company expects to report 12-month follow-up data from Dose 1 and interim data from Dose 2 in the second half of 2025.
  • FTD-C9orf72: Dosing is expected to initiate in the first half of 2025 following positive regulatory feedback.
• Subsequent Event: On May 7, 2025, the company amended its Gemma Sublicenses, increasing the aggregate initial payments to $15 million (up from $10 million) and adding a $5 million contingent milestone payment.
• Listing Status Risk: The company's stock was transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market in January 2025 due to failure to meet the $1.00 minimum bid price requirement. The company must regain compliance (maintain $1.00 bid price for 10 consecutive days) by July 28, 2025, or face delisting. A reverse stock split is being sought.
• Litigation: A pending appeal regarding a former employee lawsuit (terminated in the company's favor in December 2024) remains outstanding.

Investor Verification Checklist

• Revenue Recognition: Verify the timeline for recognizing the $8.7 million in deferred payments from Gemma Biotherapeutics, as this is a key near-term revenue driver.
• Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by July 28, 2025, to avoid delisting.
• Cash Burn Rate: Confirm that the reduced operating expenses post-restructuring align with the projected runway into Q1 2027.
• Clinical Safety: Review upcoming data releases regarding Dose 2 of PBFT02, specifically regarding the revised immunosuppression regimen and safety profile compared to Dose 1.
• Asset Sales: Track the collection of the remaining $0.6 million in proceeds from the sale of laboratory equipment.